FDA Can Disclose Supply Chain Info During Health Crises

The Department of Justice's Office of Legal Counsel issued a significant opinion on October 26, 2026, regarding the Food and Drug Administration's (FDA) ability to disclose supply chain information during foodborne illness outbreaks and recalls. This ruling clarifies that the FDA can amend its regulations to allow such disclosures in situations where there is an imminent danger to public health or gross deception of consumers. This decision could greatly impact how food safety is managed and how information is shared with the public during health emergencies.

The opinion is particularly relevant to consumers and businesses in the food industry, as it addresses the balance between protecting trade secrets and ensuring public safety. By potentially allowing the FDA to share more information about food supply chains, the ruling aims to enhance transparency and protect consumers from unsafe food products.

Background

The FDA, under the Department of Health and Human Services, is responsible for ensuring the safety and proper labeling of food and drugs. However, current FDA regulations restrict the disclosure of supply chain information, which is considered confidential commercial information. This limitation has raised concerns during foodborne illness outbreaks when timely information could help prevent further illness.

The inquiry into the FDA's authority to disclose such information arose from ongoing discussions about the need for transparency in food safety. The Trade Secrets Act, which dates back to 1864, prohibits government employees from disclosing proprietary information unless authorized by law. This led to questions about whether the FDA could disclose supply chain information without violating this act.

The FDA's current regulations limit disclosure primarily to situations involving administrative or court enforcement actions, making it challenging to provide timely information during food safety crises. The legal opinion sought to clarify the FDA's authority to amend its regulations to allow for broader disclosure in urgent situations.

The Ruling

The court ruled that while current regulations generally prevent the FDA from disclosing supply chain information, the agency has the authority to amend these regulations. Specifically, under 21 U.S.C. § 375(b), the FDA can permit disclosure in cases of imminent danger to health or gross deception of consumers. The opinion states, "Under current regulations, FDA is generally not authorized to disclose supply chain information, and therefore the Trade Secrets Act prohibits divulging such information. But FDA has statutory authority to amend its regulations to allow broader disclosure of supply chain information in situations involving imminent danger to health, or gross deception of the consumer."

This ruling emphasizes that if the FDA chooses to revise its regulations to allow for such disclosures, it would not violate the Trade Secrets Act. The opinion highlights the need for a balance between protecting business confidentiality and ensuring public safety during health emergencies.

Impact

This opinion could lead to significant changes in how the FDA handles supply chain information during foodborne illness outbreaks. By allowing for broader disclosure, the FDA can potentially provide consumers with critical information that could prevent illness and save lives. The ruling also sets a precedent for how regulatory agencies can navigate the complexities of trade secrets while prioritizing public health.

The impact of this decision extends beyond just the FDA; it affects food producers, retailers, and consumers alike. Food businesses may need to prepare for increased scrutiny and potential disclosure of their supply chain information during health crises. Consumers, on the other hand, could benefit from greater transparency and quicker access to information about food safety risks.

What's Next

The FDA now has the opportunity to amend its regulations to allow for the disclosure of supply chain information in urgent situations. This ruling does not prevent the possibility of appeals or further legal challenges, but it provides a clear pathway for the FDA to enhance its transparency efforts in protecting public health. Details were not available in the court filing regarding any related cases or potential appeals.